RxDoctor Payments Data

Edward Garner, MD

Pulmonary Disease · Augusta, GANPI 1588685382

Payments from drug & device makers

$4,237in general payments, 2019–2025

Across 269 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$751
  • Philips North America LLC$394
  • Sanofi$260
  • Insmed, Inc.$228
  • Mylan Specialty L.p.$147
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,97894%
  • Education$2596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,237 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$153,096
Medicare patients
535
Services billed
2,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter861$660,780
OpsumitMacitentan31$383,173
Dupixent SyringeDupilumab89$339,183
Prolastin CAlpha-1-Proteinase Inhibitor18$204,490
OfevNintedanib Esylate12$156,004
Breo ElliptaFluticasone/Vilanterol177$90,790
Breztri AerosphereBudesonide/Glycopyr/Formoterol134$89,390
Spiriva RespimatTiotropium Bromide59$46,621
NucalaMepolizumab13$46,304
SymbicortBudesonide/Formoterol Fumarate109$38,383
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$33,130
Stiolto RespimatTiotropium Br/Olodaterol Hcl52$28,973
Albuterol Sulfate HfaAlbuterol Sulfate666$20,028
Combivent RespimatIpratropium/Albuterol Sulfate27$17,767
Incruse ElliptaUmeclidinium Bromide36$12,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$1,193$843,3851,156 claims
Actelion Pharmaceuticals US, Inc.Opsumit$119$383,17331 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$94$249,365150 claims
Grifols USA, LLCProlastin C$143$204,49018 claims
AstraZenecaBreztri Aerosphere, Symbicort$751$127,773243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →